Globus Medical Soars 40.4% on Analyst Upgrades, Record Q3 Earnings, Raised Guidance

The share price rose to its highest level so far this month, with an intraday gain of 3.90%.

Globus Medical’s recent rally reflects a confluence of analyst upgrades, strong third-quarter results, and revised revenue guidance. BofA Securities and Wells Fargo both raised price targets for GMED, with BofA moving to “buy” from “neutral” and setting a $91 target, a 47% premium to its prior close. The company’s Q3 net income surged 129% year-over-year to $118.97 million, driven by robust demand for its minimally invasive spine care solutions and disciplined cost management. Revenue climbed 22.9% to $769 million, outpacing expectations.

Full-year 2025 revenue guidance was raised to $2.86 billion–$2.9 billion, reflecting confidence in both domestic and international market momentum. CEO Keith Pfeil emphasized innovation and operational execution, aligning with broader trends in value-based care and cost-effective surgical technologies. The stock’s 40.4% three-day gain underscores investor optimism about sustained growth in a sector poised to benefit from aging demographics and technological advancements in spinal treatments.